Application of proton pump inhibitors in acute-on-chronic liver failure
10.3969/j.issn.1001-5256.2022.12.035
- VernacularTitle:质子泵抑制剂在慢加急性肝衰竭治疗中的应用
- Author:
Yuhao YAO
1
,
2
;
Xiao XIA
3
;
Jiaxin ZHANG
2
,
4
;
Xiaoke LI
2
,
4
;
Yong'an YE
2
,
4
Author Information
1. The First Clinical Medical School, Beijing University of Chinese Medicine, Beijing 100029, China
2. Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
3. Department of Pneumology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
4. Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100700, China
- Publication Type:Reviews
- Keywords:
Liver Failure;
Proton Pump Inhibitors;
Therapeutic Uses
- From:
Journal of Clinical Hepatology
2022;38(12):2864-2867
- CountryChina
- Language:Chinese
-
Abstract:
Proton pump inhibitors (PPIs) are commonly used in clinical practice and are currently widely used in people with acute-on-chronic liver failure (ACLF). However, such medication is still not supported by the recommendations in the latest version of Clinical guidelines for acute-on-chronic liver failure issued by American College of Gastroenterology. With reference to the guidelines or consensus statements in China and globally and the latest research advances, this article elaborates on the indications, possible benefits, and potential risks of PPIs used in people with ACLF, in order to provide a reference for the standardized use of PPIs in the population with ACLF in clinical practice.
